March 24 (Reuters) - Clover Biopharmaceuticals 2197.HK:
ANNOUNCES U.S. IND CLEARANCE AND INITIATION OF REVACCINATION CLINICAL STUDY FOR RSV VACCINE CANDIDATE SCB-1019 BY US FDA
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
March 24 (Reuters) - Clover Biopharmaceuticals 2197.HK:
ANNOUNCES U.S. IND CLEARANCE AND INITIATION OF REVACCINATION CLINICAL STUDY FOR RSV VACCINE CANDIDATE SCB-1019 BY US FDA
Further company coverage: 2197.HK
((Reuters.Briefs@thomsonreuters.com;))
Comments